Completado

SAD30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está evaluando

goLITE

+ Control

Dispositivo
Quiénes están siendo reclutados

Trastorno depresivo

+ Trastornos Mentales

De 21 a 64 años
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio de Tratamiento

Intervencional
Inicio del estudio: enero de 2012
Ver detalles del protocolo

Resumen

Patrocinador PrincipalPhilips Respironics
Última actualización: 27 de enero de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 6 de enero de 2012

Fecha en la que se inscribió al primer participante.

Participants will be randomly assigned to receive either a 467nm light or a 580nm light. Participants will use the light every day for six weeks for 30 minutes. Multiple assessments and questionnaires will be given weekly to assess the efficacy of the treatment.

Título Oficial30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder
NCT01462305
Patrocinador PrincipalPhilips Respironics
Última actualización: 27 de enero de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 35 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Estudio de Tratamiento

Estos estudios prueban nuevas formas de tratar una enfermedad, condición o problema de salud. El objetivo es determinar si un nuevo medicamento, terapia o enfoque funciona mejor o tiene menos efectos secundarios que las opciones existentes.



Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

De 21 a 64 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos no permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

Trastorno depresivoTrastornos Mentales

Criterios

Inclusion Criteria: 1. Males and females, ages 21-64 2. Able and willing to provide written informed consent 3. History of recurrent major depressive episodes with winter-type seasonal pattern by Diagnostic and Statistical Manual of the American Psychiatric Associated, 4th Ed. (DSM-IV) criteria (American Psychiatric Association, 1990), based on diagnostic interview utilizing the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First et al., 2007) \*Bipolar I excluded for this study 4. SIGH-ADS score of ≥20 5. Use of the light device as instructed by the study clinician for at least 6 out of 7 days for the first two weeks of therapy and at least 5 out of 7 days for the remaining four weeks of therapy. Exclusion Criteria: 1. Participation in a study of investigational or marketed drugs or devices during the 30-day period prior to the start of the study or during the study 2. Subjects who are medically complicated, medically unstable and/or have other severe diseases, as determined by the investigator. 3. Abnormal TSH level, (outside range of 0.3 to 5.0 mlU/L), as determined by the TSH levels blood test 4. History of concurrent psychiatric illness that would preclude compliance with the protocol and/or ability to complete the study safely 5. History or current diagnosis of Bipolar I Disorder 6. Variable psychiatric symptoms such as rapid cycling or severe premenstrual syndrome that could interfere with accurate assessment of the treatment effect 7. History of a medical condition that affects mood or produces hallmark symptoms of a mood disorder (i.e. hypothyroidism) 8. History of current or recent (within previous 12 months) alcohol, narcotic or other drug abuse by DSM-IV criteria 9. Positive urine drug screen at the Physical Screening 10. Active suicidal or homicidal ideation or plan, as determined by the investigator 11. Global Assessment of Functioning (GAF) \<51 (see Appendix B) 12. Use of light therapy treatment within the previous 6 months or any history of goLITE use 13. Pregnant or lactating (will confirm absence of pregnancy with a urine or serum pregnancy test in females of childbearing potential during the Physical Screening. Additional pregnancy tests may be performed as per individual site requirements). Females of child-bearing potential must agree to use some form of birth control throughout the course 14. Current use or use within 2 months of antidepressants or mood stabilizing medications, even if taken for a non-psychiatric indication 15. Currently working night shift or rotating shift or other habitual alteration of the sleep/wake cycle 16. Planned travel outside of the state in which the trial is being conducted 17. Current use or use within the previous 1 month of photosensitizing medications (amiodarone, benoxaprofen, chlorpromazine, demeclocycline, fleroxacin, nalidixic acid, ofloxacin, piroxicam, porfimer, psoralens, quinidine, temoporfin) or remedies (St. John's wort, melatonin) 18. History of eye trauma or disease, retinopathy, and/or cataract of a level that would significantly affect transmission or processing of light through either eye 19. Ishihara score of \<10 on the Ishihara Test for Color Deficiency 20. Use of medications, such as tetracycline or oral isoretinoin (Accutane), that would affect the safety of light exposure treatment or that causes complaints of eyestrain or abnormal tearing with computer use of up to 30 minutes at a time

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

2 grupos de intervención están designados en este estudio

0% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Grupo I

Experimental
light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks

Grupo II

Comparador Activo
light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks

Objetivos del Estudio

Objetivos Primarios

Objetivos Secundarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene 4 ubicaciones

Suspendido

McLean Hospital

Belmont, United StatesAbrir McLean Hospital en Google Maps
Suspendido

Brigham & Women's Hospital

Boston, United States
Suspendido

University of Minnesota

Minneapolis, United States
Suspendido

Community Research Management Associates

Cincinnati, United States
Completado4 Centros de Estudio